August 25, 2020 8:30 am EST Immunovant Announces Positive Topline Results from ASCEND MG, A Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
March 30, 2020 8:30 am EST Immunovant Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a trial of IMVT-1401 In Thyroid Eye Disease, and Provides Corporate Update